Despite rumors (or perhaps hopes) that GlaxoSmithKline plc might follow recent news from Pfizer Inc. and Merck & Co. Inc. with its own mega-merger, the London-based pharma firm has opted for a more modest venture, pooling its HIV portfolio with Pfizer's in an unusual display of cooperation between pharmaceutical competitors. (BioWorld Today) Read More
